Therapy abandonment in specialty pharma is often treated like an adherence problem. In practice, a meaningful share of abandonment starts earlier, before the patient ever begins therapy. Coverage checks, prior authorization, missing documentation, denial notices, long response times, and affordability questions can create so much friction that patients disengage before the program has a chance to deliver value. That is why reimbursement support programs matter: they are one of the few patient support program functions designed to reduce drop-off at the exact moment access becomes difficult.

Why specialty pharma drop-off happens before the first fill

Specialty pharma products are especially vulnerable to front-end drop-off because the path from prescription to start is rarely simple. A patient may be asked for coverage details, the provider may need to submit prior authorization documentation, the payer may request more information, and the out-of-pocket amount may not be clear until late in the process. The most recent AMA prior authorization physician survey found that 95% of physicians said prior authorization delays needed care, and 79% said it can at least sometimes lead to treatment abandonment. The same survey also found that physicians and staff spend an average of 13 hours each week completing prior authorizations.

Government oversight findings reinforce that this is not only a perception problem. In a 2022 report, the HHS Office of Inspector General found that some Medicare Advantage organizations delayed or denied access even when requests met Medicare coverage rules. In the OIG’s sample, 13% of denied prior authorization requests met those rules and likely would have been approved under original Medicare. The report also noted that avoidable delays and extra steps create friction for patients and providers alike.

Affordability adds a second layer of risk. CDC data shows that in 2021, 9.2 million adults ages 18 to 64 who used prescription medication reported skipping doses, taking less medication, or delaying a fill to reduce costs. Among uninsured adults who took prescription medication, 22.9% reported not taking it as prescribed due to cost. In other words, even when coverage exists, patient affordability can still break the journey. CMS has responded to that broader affordability pressure by requiring Medicare Part D plans to offer the Medicare Prescription Payment Plan beginning in 2025, allowing eligible members to spread out-of-pocket costs over monthly payments rather than paying everything at the pharmacy counter at once. 

What reimbursement support programs change

A strong reimbursement support program reduces abandonment by treating access as an active workflow, not a passive queue. That usually means verifying benefits quickly, initiating prior authorization as early as possible, following up with payers before deadlines slip, capturing specific denial reasons, supporting appeals where appropriate, and screening patients for applicable financial assistance pathways that fit the program and payer rules. CMS’s current prior authorization rule for affected public-program payers points in the same direction: urgent decisions within 72 hours, standard decisions within seven calendar days, specific denial reasons, and public reporting of prior authorization metrics. Those are exactly the kinds of service standards commercial patient support leaders should expect internally as well.

In practice, this work is easier when programs have structured workflows, integrated communications, and real-time reporting rather than disconnected handoffs. A light-touch example of how modern patient support infrastructure is often described as configurable workflows, omnichannel communications, integration with third-party systems, and dashboard reporting that helps teams see where patients are getting stuck. Those capabilities are not the strategy by themselves, but they make it much easier to operationalize the strategy consistently. 

Common reimbursement support interventions

The table below translates the documented barriers of delay, denial friction, and cost pressure into the most common reimbursement support interventions. The expected impact is directional rather than guaranteed; results will vary by brand, payer mix, distribution model, and how “abandonment” is defined.

The underlying logic is simple. If prior authorization delays push patients out of the funnel, then faster submissions and faster follow-up should reduce drop-off. If some denials are avoidable or reversible, then clear denial management and appeals support should keep more patients moving forward. If cost causes people to delay or skip medication, then affordability workflows should reduce abandonment risk before the first fill. The exact size of the improvement will differ by program, but the mechanism is strong and evidence-based.

What decision-makers should measure

For market access leaders and patient services directors, the key mistake is measuring reimbursement support only as productivity. The better lens is conversion. Useful metrics include referral-to-benefits-verification time, time from complete case to prior authorization submission, time to payer decision, first-pass approval rate, appeal rate, overturn rate, percent of patients screened for affordability support, and abandonment before first fill or shipment. CMS is already pushing the system toward greater prior authorization transparency through denial reasons and public metrics, which makes this kind of visibility even more important for commercial programs.

It also helps to set one operational definition of therapy abandonment and stick to it. For example, a brand might define it as no first fill within 30 days of a complete referral, or no confirmed start after approval. What matters is consistency. Once the definition is stable, leaders can compare abandonment by payer type, region, channel, denial reason, or affordability status and learn where reimbursement support is making the biggest difference.

The broader takeaway is that reimbursement support programs reduce therapy abandonment when they remove friction early, keep denied cases alive, and address affordability before patients fall out of the journey. In specialty pharma, that makes reimbursement support not just an administrative service, but one of the most important access levers a patient support program can own.

Summary

The strongest case for reimbursement support programs is operational, not theoretical: many patients abandon therapy before the first fill because prior authorization, documentation gaps, denial handling, and affordability questions create too much friction. Recent data from the AMA, HHS OIG, CDC, and CMS all point in the same direction: when access barriers are resolved faster and more transparently, fewer patients are left waiting, dropping off, or walking away from treatment.